Dhasolone

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dhasolone

What is Dhasolone?

Dhasolone is a pharmaceutical formulation containing prednisolone, a synthetic glucocorticoid derived from cortisol. It is classified as a corticosteroid with potent anti-inflammatory and immunosuppressive properties. The medication is designed to mimic the effects of hormones naturally produced by the adrenal glands to manage a wide range of conditions characterized by inflammation and overactive immune responses.

Mechanism of Action

The active ingredient, prednisolone, works by entering target cells and binding to specific glucocorticoid receptors. This process influences gene expression, leading to the following physiological effects:

  • Reduction of Inflammation: It inhibits the production of inflammatory chemicals, such as prostaglandins and leukotrienes, and stabilizes lysosomal membranes to prevent the release of enzymes that damage tissues.
  • Immune System Modulation: It reduces the activity and volume of the lymphatic system, lowering the production of antibodies and suppressing the migration of white blood cells to sites of inflammation.

Therapeutic Use Cases

As a versatile corticosteroid, Dhasolone is utilized across various medical specialties to provide symptomatic relief and disease management. Common areas of application include:

  • Allergic Conditions: Management of severe allergic reactions, drug hypersensitivity, and perennial or seasonal allergic rhinitis.
  • Dermatological Diseases: Treatment of inflammatory skin conditions such as severe psoriasis, pemphigus, and exfoliative dermatitis.
  • Endocrine Disorders: Used in the management of primary or secondary adrenocortical insufficiency.
  • Gastrointestinal Diseases: Helping to manage acute episodes of regional enteritis (Crohn's disease) and ulcerative colitis.
  • Hematologic Disorders: Management of certain types of anemia and thrombocytopenia.
  • Rheumatic and Autoimmune Disorders: Short-term administration for acute episodes or exacerbations of rheumatoid arthritis, systemic lupus erythematosus, and acute gouty arthritis.
  • Respiratory Diseases: Treatment of bronchial asthma, aspiration pneumonitis, and sarcoidosis.

Regulatory References

  1. National Institutes of Health

What side effects are possible with Dhasolone?

Possible Side Effects and Safety Information: Dhasolone

Primary Ocular Risks and Serious Adverse Reactions

The safety profile of Dhasolone, which contains prednisolone acetate ophthalmic suspension, is primarily defined by local Eye Disorders that are typically associated with prolonged exposure. Regulatory documents classify the most serious documented risks as elevated intraocular pressure (IOP), which may lead to glaucoma and subsequent optic nerve damage and defects in the visual field. Another serious, cumulative risk is the formation of a posterior subcapsular cataract.

Less frequent but documented serious events include globe perforation in cases of pre-existing thin corneal or scleral tissue, and the development of secondary ocular infections (viral, fungal, or bacterial) due to the drug's immunosuppressive action in the eye.

Time-Related Patterns and Safety Constraints

Prolonged use is the key regulatory safety pattern; the risk of glaucoma and cataract formation is increased with extended application. If the product is used for ten days or longer, official labeling states that intraocular pressure should be routinely monitored. The suspension is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial Herpes Simplex keratitis, as well as in mycobacterial and fungal diseases of the ocular structures, as these infections can be masked or enhanced.

Other Adverse Reactions and Population Notes

Commonly reported local reactions include transient burning, stinging, foreign body sensation, or ocular irritation upon instillation. In specific populations, the documentation notes that pediatric patients may be at greater risk for IOP elevation and, rarely, for systemic effects like adrenal suppression. The use in pregnancy or during lactation should only be considered when the potential benefit outweighs the potential risk to the fetus or infant.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Dhasolone (Prednisolone Acetate Ophthalmic Suspension) is considered low risk when used as directed due to the topical route of administration. Official government labeling addresses two primary scenarios: massive acute accidental ingestion and chronic systemic toxicity from prolonged, excessive use.


Overdose Scope

Key Element Regulatory Statement
Overdose Presentations Acute systemic overdose is typically non-life threatening. Chronic toxicity manifests as cushingoid features (e.g., Moon face, hypertension).
Exposure-Related Factors Risk is associated with massive acute accidental ingestion or prolonged, excessive use.
Population-Specific Notes Children and infants may exhibit greater susceptibility to systemic effects.
Emergency-Response Seek immediate medical attention for massive acute accidental ingestion. Consult a doctor for signs of chronic toxicity.

Management and Antidote Status

Classification Aspect Regulatory Description
Severity Classification Acute symptoms are generally reversible. Chronic toxicity is manageable upon gradual withdrawal.
Antidote Status No specific antidote is known for prednisolone overdose.

Official Overdose Statements

  • For known or suspected massive acute accidental ingestion, immediate medical attention is required.
  • The management for acute overdose involves symptomatic and supportive treatment.
  • Prolonged, excessive use can lead to signs of chronic systemic toxicity, requiring medical assessment.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile by contrasting the low acute risk from normal use with the need for immediate medical attention for massive accidental ingestion. The information requires symptomatic and supportive treatment and highlights the potential for reversible cushingoid manifestations arising from chronic excessive use, with a specific note regarding increased susceptibility in pediatric patients.

Therapeutic Uses of Dhasolone

What Dhasolone Treats: Main Uses and Benefits

Dhasolone, which contains prednisolone, is used for managing a wide range of conditions where additional symptomatic support is needed. It is applied across domains involving conditions presenting with systemic or localized discomfort.

The medicine is used for therapeutic areas affecting various organ systems. These conditions are typically characterized by symptoms related to systemic imbalance or heightened physiological activity, such as physical discomfort or symptoms that create noticeable physiological strain.

Prednisolone is commonly used across conditions presenting with acute episodes in therapeutic areas such as rheumatic disorders, various allergic states, diseases of the respiratory system and eyes, dermatologic conditions, and certain gastrointestinal and hematologic disorders. The medicine is relevant when supportive symptom management is appropriate, such as in contexts involving heightened systemic burden or during phases when symptoms become more noticeable.

The medicine supports general well-being during symptomatic phases and assists with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relief for Symptoms related to physical discomfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Dhasolone?

This section describes the official population eligibility and contraindication rules for Dhasolone (Prednisolone Acetate Ophthalmic Suspension), as stated in regulatory documents.


Absolute Non-Eligibility (Contraindications)

Dhasolone must not be used by individuals with known or suspected hypersensitivity to Prednisolone Acetate or any component of the drug. Its use is also contraindicated in patients with specific ocular infections, including most viral diseases of the cornea and conjunctiva (such as epithelial herpes simplex keratitis), fungal diseases of ocular structures, mycobacterial infection of the eye, and acute untreated purulent ocular infections.


Restricted and Conditional Use

Population Group Regulatory Status and Constraint
History of Ocular Herpes Use requires great caution due to the risk of exacerbation.
Glaucoma/Thin Cornea Use with caution due to the risk of increased intraocular pressure (IOP) or perforation.
Long-Term Use Requires routine IOP monitoring for all patients using the drug for 10 days or longer.
Pregnancy/Lactation Use is restricted, requiring a judgment on whether the potential benefit justifies the potential risk to the fetus or infant.

Age-Group Eligibility

The medicine is generally established for use in adults and geriatric patients. Safety and effectiveness have also been established in pediatric patients for specific formulations, although mandatory IOP monitoring in children may be difficult.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Official regulatory documents identify an important pharmacokinetic interaction involving CYP3A inhibitors. This medicinal product category includes specific agents such as cobicistat-containing products. The interaction is mechanistically based on the inhibition of the Cytochrome P450 3A (CYP3A) enzyme, which is responsible for clearing the corticosteroid component after minimal systemic absorption. This reduced clearance results in an elevated systemic exposure of the prednisolone and increases the overall risk of systemic side-effects. No other drug–drug, drug–food, alcohol, or herbal product interactions are documented in the official prescribing information for the ophthalmic suspension. Furthermore, no mandatory timing-based administration rules requiring dose separation are specified in relation to any known interaction.


Interaction Classifications and Restrictions

The documented interaction with CYP3A inhibitors is classified as clinically significant, leading to a formal regulatory restriction. Co-treatment with these substances, particularly cobicistat-containing products, should be avoided unless the prescribing authority determines that the clinical benefit outweighs the increased systemic risk. This high-level classification underscores the need for monitoring when such co-administration is deemed necessary. The official product labeling contains no population-specific notes regarding the differential severity of this drug interaction in patient groups such as those with hepatic impairment.


Connection to the overall interaction profile

Regulatory information defines the product’s interaction structure as narrow and highly focused on the consequences of CYP3A inhibition. This single restriction covers the entirety of the documented drug interaction profile, with no stated constraints concerning timing, food, or other substances.

Mechanism of Action

Dhasolone's mechanism of action is mediated by its active ingredient, Prednisolone Acetate, a synthetic glucocorticoid that modulates the physiological inflammatory response through targeted molecular interactions. The core mechanism is achieved via two complementary domains:

Regulating Inflammatory Gene Expression

The drug's primary action is the agonism of the intracellular Glucocorticoid Receptor (GR), initiating a cascade known as the genomic effect. The activated drug-receptor complex enters the nucleus and suppresses the activity of major pro-inflammatory transcription factors, such as NF-κB. This intervention cuts off the signal to synthesize key inflammatory mediators like cytokines and chemokines, which limits the proliferation of immune cells and their subsequent accumulation in affected tissue.

Suppression of Vasoactive Mediators and Exudation

A secondary but critical mechanistic domain involves inhibiting the synthesis of lipid-based mediators. The drug indirectly blocks the enzyme Phospholipase A₂ (PLA₂), the essential precursor for generating prostaglandins and leukotrienes (eicosanoids). By suppressing the production of these vasoactive chemicals, the mechanism effectively reduces vascular permeability and vasodilation, which promotes reduced vascular changes at the local level and decreases tissue exudation.

Dosage and Administration Information

How to Use Dhasolone

This section describes the administration and dosing regimen for Dhasolone (Prednisolone Acetate Ophthalmic Suspension 1%).


Administration Scope

Entity Instruction
Route of Administration Topical ophthalmic instillation (ocular application). The product is explicitly labeled not for injection or oral use.
Dosing Schedule (General) The typical initial dose is 1 to 2 drops instilled into the conjunctival sac.
Frequency Pattern Therapy begins with a standard frequency of 2 to 4 times per day. For severe or acute presentation, the frequency may be increased to up to 2 drops every hour during the initial 24 to 48 hours.
Preparation Requirement The suspension must be shaken well before using to ensure uniform dispersion of the active ingredient, Prednisolone Acetate.
Post-Instillation Procedure To reduce systemic absorption, punctal occlusion (light pressure on the inner corner of the eye) for 1 minute following instillation is recommended.
Duration Pattern The dosage frequency must be gradually reduced (tapered) as a favorable response is observed, with caution against premature discontinuation.

Population-Specific Use

No adjustment is required for older adults (geriatric population). However, the safety and efficacy of the suspension have not been established in pediatric patients, and therefore, no specific pediatric posology can be recommended.


Connection to the Overall Use Protocol

These instructions define Dhasolone use as a topical, preparation-dependent regimen governed by a titration-based schedule. The protocol mandates a standardized high-frequency start followed by a required tapering phase to determine the shortest necessary course, ensuring delivery via the ocular surface while minimizing systemic uptake through specific administration techniques.

Recent Clinical Evidence

Recent Clinical Evidence


1. Core Research Findings

Research has explored whether Dhasolone is a treatment for the condition. Study endpoints typically measured several outcomes, including subjective well-being and changes in symptom severity.

One key study evaluated whether the drug affected quality of life across several domains. The trial monitored participants for three months. A majority of the observed outcomes were recorded within the expected range for the condition, and findings were mixed across different patient groups.

2. Research into Combination Therapy

A second line of research examined whether the combination affected pain scores and how it interacted with other standard-of-care treatments. Studies have not compared the drug's effect to other treatments. Research explored whether patient activities also affected the measured outcome.

This research generally involved small sample sizes and did not use a control group, which limits the conclusions that can be drawn about the findings. The combination was examined for its association with the rate of flares in a small subset of participants over six months.

3. Safety and Tolerability

The study protocol included examinations of the occurrence of side effects, including gastrointestinal discomfort and headache. The study protocol included participants with various health profiles.

The majority of adverse events recorded were classified as mild-to-moderate. Evidence remains limited regarding the long-term safety profile beyond the 12-month mark. Further research is necessary to fully characterize the long-term impact of the drug.

Frequently Asked Questions (FAQ)

Common questions about Dhasolone (FAQ)

Q: How quickly does Dhasolone start working for inflammation?

A: Regulatory documents state that for severe or acute ocular inflammation, the dosing frequency may be increased significantly during the initial 24 to 48 hours. This indicates the product’s dosing protocol is intended to target acute inflammatory presentations.


Q: Is it okay to drink coffee or caffeine while taking Dhasolone?

A: According to the official product information, there is no documented interaction between this specific ophthalmic suspension and coffee, caffeine, other foods, or beverages. The drug is designed for local action in the eye, which minimizes systemic concerns typically associated with oral medicines.


Q: Is Dhasolone a maintenance drug or is it only used short-term?

A: Official guidelines describe Dhasolone’s use as generally short-term. The dosage must be gradually reduced (tapered) as the condition improves. Prolonged use is associated with an increased risk of serious ocular side effects, such as glaucoma and cataract formation.


Q: What are the most common stomach-related side effects of Dhasolone?

A: The most common reported side effects for this eye drop are related to local application, such as burning, stinging, or irritation in the eye. Although gastrointestinal discomfort is sometimes noted in clinical data, it is not a primary concern for this specific ophthalmic formulation.


Q: Is Dhasolone considered safe for long-term use?

A: Official warnings describe an increased risk of serious side effects with prolonged use, including glaucoma and cataract formation. If the medicine is used for ten days or longer, intraocular pressure (IOP) must be routinely monitored.


Q: What are the signs of an allergic reaction to Dhasolone?

A: Signs of a hypersensitivity (allergic) reaction may include skin reactions such as rash, hives, or swelling of the face, lips, tongue, or throat, which may be indicators of a serious reaction. The medicine is formally contraindicated if a hypersensitivity to any of its components is known or suspected.


Q: What happens if I stop taking Dhasolone suddenly?

A: Regulatory documents indicate that the dosage frequency must always be gradually reduced (tapered) to prevent the underlying inflammation from returning sharply. Systemic effects, such as adrenal suppression, have been reported in rare cases associated with frequent use, particularly in pediatric patients.


Q: Is Dhasolone used to treat autoimmune disorders?

A: Dhasolone is classified as a corticosteroid with a localized immunosuppressive action in the eye. It is indicated for steroid-responsive inflammatory conditions of the eye, which may include some forms of inflammation linked to autoimmune processes, but it does not treat the underlying systemic autoimmune disorder.


Q: How effective is Dhasolone based on clinical research?

A: Dhasolone is classified as a corticosteroid, which has an established function for controlling ocular inflammation. Clinical studies have shown mixed results on measures like patient quality of life across various groups, and the research often involves small sample sizes, which limits a definitive, broad conclusion.


Q: Why is Dhasolone used for so many different conditions?

A: The drug's active ingredient is a glucocorticoid that targets the fundamental mechanism of inflammation (swelling, redness, irritation). Because inflammation is a common component of many different eye diseases (like iritis or keratitis), the medicine is indicated for a wide range of steroid-responsive conditions.


Q: What percentage of patients experience side effects from Dhasolone?

A: Official documents list the adverse reactions in a general order of frequency, with elevated intraocular pressure (IOP) being the most frequent serious risk. However, the product labeling does not provide a specific overall percentage or incidence rate for the total patient population that experiences side effects.


Q: Does Dhasolone cause weight gain?

A: Weight gain is not listed as a common side effect of this ophthalmic suspension. However, in rare instances of high systemic absorption, particularly with frequent use in children, a patient may experience systemic effects associated with corticosteroids, such as adrenal suppression, which can involve weight changes.


Q: Can Dhasolone cause insomnia or trouble sleeping?

A: Insomnia or trouble sleeping is not a commonly reported local side effect of the eye drops. While systemic corticosteroids can cause behavioral and sleep changes, this product is designed to minimize systemic exposure. Patients are advised to note any significant or unusual mental changes mentioned in the product information.


Q: What should I do if I missed a dose of Dhasolone?

A: Official regulatory documents contain guidelines on how to proceed if a planned administration is missed. These guidelines typically specify that a double dose should not be used to compensate for a single missed dose.


Q: Is there a generic version of Dhasolone available?

A: Yes, Dhasolone's active ingredient, prednisolone acetate ophthalmic suspension, is generally available from various manufacturers in generic form in addition to its brand-name presentations.


Q: Will Dhasolone make me feel tired or drowsy?

A: Tiredness or drowsiness is not a common local side effect. However, unusual weakness or tiredness is listed in the product information as a potential symptom of rare systemic complications, such as adrenal insufficiency.


Q: How long does Dhasolone stay in your system?

A: The drug is designed for local action in the eye. Its active component clears rapidly from the local fluid, with official data indicating half of the drug is cleared within approximately 30 minutes of application. This rapid clearance helps limit systemic exposure.


Q: Does Dhasolone affect my mood?

A: Mood changes are not listed as a common side effect of the eye drops. However, systemic corticosteroids can sometimes cause mood swings. Significant or severe mood or mental changes are noted in the product information as symptoms to be aware of.


Q: What should I know about Dhasolone and driving?

A: The official labeling indicates that the product may cause blurred vision or other visual disturbances immediately after instillation. Patients should wait until vision is clear before performing activities such as driving or operating machinery.


Q: Is Dhasolone safe for people with diabetes?

A: Systemic corticosteroids have the potential to raise blood sugar levels. Although Dhasolone is an eye drop with minimal systemic absorption, official documents indicate that people with diabetes may need to have their glucose levels closely monitored when using the medication.


Q: What does 'contraindication' mean in relation to Dhasolone?

A: A contraindication is a condition or circumstance that makes the use of the drug inadvisable or potentially harmful. For Dhasolone, examples include specific existing infections like most viral, fungal, or mycobacterial diseases of the eye, as the steroid could worsen these conditions.


Q: Is Dhasolone a scheduled drug (controlled substance)?

A: According to official drug classifications, Dhasolone (Prednisolone Acetate Ophthalmic Suspension) is a prescription medicine but is not classified as a controlled substance.


Q: What happens when the effects of Dhasolone wear off?

A: After the drug is cleared from the eye's fluid, its anti-inflammatory effects gradually diminish. If the underlying condition is not fully resolved, the symptoms of inflammation may return. This is why the dosing must be tapered to prevent a sudden return of symptoms.


Q: Can Dhasolone cause problems with bone density?

A: Bone density loss (osteoporosis) is a known risk associated with long-term, high-dose oral corticosteroids. Because Dhasolone is an eye drop designed for local use with minimal systemic absorption, the risk of bone density issues is considered low and has not been specifically reported for this topical product.


Q: Does Dhasolone have a risk of dependence?

A: Dhasolone is not known to have a risk of dependence or addiction. However, a gradual reduction (tapering) of the dosage is required to prevent a rebound of inflammation, which is related to the drug's potent anti-inflammatory effects, not dependence.


Q: Does Dhasolone affect the skin?

A: Skin changes are not listed as a common local side effect of the eye drop. However, rash or hives have been reported rarely as a sign of a generalized hypersensitivity (allergic reaction) to the medicine.

How should Dhasolone be stored and disposed of?

How to Store and Dispose of Dhasolone

Storage and disposal of Dhasolone (Prednisolone Acetate Ophthalmic Suspension) must strictly follow the official conditions outlined in regulatory labeling.


Official Storage Requirements

  • Temperature: Store at Controlled Room Temperature, typically up to 25 C (77 F). The product must not freeze.
  • Protection: Keep the container tightly closed and store the medicine away from light.
  • Handling: The suspension must be shaken well before using to ensure uniform content. Care should be taken to prevent contamination of the dropper tip.
  • Stability: Discard the product 28 days after first opening.
  • Safety: Always store the medicine out of the reach of children.

Disposal Instructions

Unused or expired Dhasolone must be disposed of in accordance with local guidelines. To avoid environmental harm, do not throw the medicine in the trash or pour it down the sink or toilet (wastewater) unless explicitly instructed to do so by a healthcare provider or authorized collection program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dhasolone found in:

A-Z Index: